References
- CatSalut. Guía para la definición de criterios de aplicación de esquemas de pago basados en resultados (EPR) en el ámbito farmacoterapéutico (Acuerdos de Riesgo Compartido). Barcelona: Generalitat de Catalunya, Departamento de Salut; 2014.
- Clopes A, Gasol M, Cajal R, et al. Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer. J Med Econ. 2017;20(1):1–7.
- Ferrario A, Arãja D, Bochenek T, et al. The Implementation of managed entry agreements in central and Eastern Europe: findings and Implications. Pharmacoeconomics. 2017;35(12):1271–1285.
- Adamski J, Godman B, Ofierska-Sujkowska G, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
- Gasol-Boncompte M, Mora-Ripoll R, Gilabert-Perramon A. Experiencias en acuerdos de riesgo compartido y esquemas de pago basados en resultados en Cataluña. [Online]; 2015 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/acords_risc_compartit/AES-2015_poster_68_ARC_def_09_06_2015.pdf
- Garrison LP, Towse A, Briggs A, et al. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–719.
- Nazareth T, Ko J, Sasane R, et al. Outcomes-based contracting experience: research findings from U.S. and European stakeholders. J Manag Care Spec Pharm. 2017;23(10):1018–1026.
- Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer carec. Lancet Oncol. 2014;15(3):e112–8.
- Howard DH, Bach PB, Berndt ER, et al. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–162.
- Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: justum pretium–the just price. J Clin Oncol. 2013;31(28):3600–3604.
- Cohen D. Cancer drugs: high price, uncertain value. BMJ. 2017;359:j4543.
- Patent expiry and costs for anticancer medicines for clinical use. Generics Biosimilars Initiat J. 2017;6(3):105–106.
- Hill A, Gotham D, Fortunak J, et al. Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ open. 2016;6(1):e009586.
- Hill A, Redd C, Gotham D, et al. Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis. BMJ open. 2017;7(1):e011965.
- Carlson J, Chen S, Garrison LP. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017;35(10):1063–1072.
- Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47.
- Goble J, Ung B, van Boemmel-Wegmann S, et al. Performance-based risk-sharing arrangements: U.S. payer experience. J Manag Care Spec Pharm. 2017;23(10):1042–1052.
- Yu J, Chin L, Oh J, et al. Performance-based risk-sharing arrangements for pharmaceutical products in the United States: a systematic review. J Manag Care Spec Pharm. 2017;23(10):1028–1040.
- Brown D, Sheer RB, Pasquale M, et al. Payer and pharmaceutical manufacturer considerations for outcomes-based agreements in the United States. Value Health. 2018;21(1):33–40.
- Maskineh C, Nasser S. Managed entry agreements for pharmaceutical products in Middle East and North African countries: payer and manufacturer experience and outlook. Value Health Reg Issues. 2018;16:33–38.
- Piatkiewicz T, Traulsen J, Holm-Larsen T. Risk-sharing agreements in the EU: a systematic review of major trends. Pharmacoecon Open. 2018;2(2):109–123.
- Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. London: The London School of Economics and Political Science; 2013. EMiNet, Brussels, Belgium.
- CatSalut. Catsalut web page [Online]; 2018 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/ca/coneix-catsalut/convenis-contractes/convenis/
- CatSalut. Conveni subscrit en data 13 de maig de 2013, entre el laboratori farmacèutic UCB PHARMA, SA, l’Hospital Universitari de Bellvitge i el Servei Català de la Salut, model de risc compartit en el cost, d’administració del medicament CIMZIA® [Online]; 2013 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2013/1482_13.pdf
- CatSalut. Conveni AstraZeneca i CatSalut per a la pròrroga del model de risc compratit del cost d’inhibidors de la proteïna quinasa en pacients amb càncer de pulmó metastàtic no microcític [Online]; 2013 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2013/1484_13.pdf
- CatSalut. Conveni marc de pagament per resultats de Vectibix en el tractament de pacients adults amb carcinoma colorrectal metastàtic (CCRM) amb ras no mutat (wild-type) en primera línia en combinació amb Folfox entre CatSalut i Amgen SA [Online]; 2017 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2017/1628-17.pdf
- CatSalut. Conveni marc de risc compartit i de pagament per resultats de Keytruda (Pembrolizumab) en el tractament de melanoma avançat (Irressecable o metastàtic) entre el CatSalut i Merck Sharp & Dohme de España, SA (MSD) [Online]; 2017 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2017/1629-17.pdf
- CatSalut. Conveni marc de pagament per resultats de Fampridina per la millora de la marxa en pacients amb esclerosi múltiple amb discapacitat de la marxa entre el CatSalut i Biogen Spain, S.L [Online]; 2017 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2017/1631-17.pdf
- CatSalut. Conveni marc de pagament per resultats de Perjeta (pertuzumab) en combinació amb Herceptin en el tractament neoadjuvant del càncer de mama HER2-positiu, entre el CatSalut i Roche Farma, SA [Online]; 2017 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2017/1644-17.pdf
- CatSalut. Conveni marc de pagament per resultats de Mekinist en combinació amb Tafinlar indicat pel tractament del pacients adults amb melanoma no ressecable o metastàtic amb mutació BRAF V600 entre el CatSalut i Novartis Farmacéutica, S.A [Online]; 2017 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2017/1645-17.pdf
- CatSalut. Adenda al conveni de pagament per resultats de cetuximab en primera línia càncer colorectal metastàtic entre CatSalut i Merck subscrit entre el CatSalut i Merck, SLU en data 5 d’abril de 2016 [Online]; 2017 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2017/1638-17.pdf
- CatSalut. Conveni marc regulador d’un acord de risc compartit basat en resultats financers de tolvaptan (Jinarc), per a poliquístosis renal autosòmica dominant (PQRAD) de ràpida progressió entre CatSalut i Otsuka Pharmaceutical, SA [Online]; 2018 [cited 2018 Jul]. Available from: http://catsalut.gencat.cat/web/.content/minisite/catsalut/coneix_catsalut/convenis_contractes/convenis/2018/1676-18.pdf
- Rojas García P, Antoñanzas Villar F. Los contratos de riesgo compartido en el sistema nacional de salud: percepciones de los professionales sanitarios. [Risk sharing contracts in the national health care system: perceptions of health care professionals]. (Spanish). Rev Esp Salud Publica. 2018;92(4):e20.
- Dunlop WC, Staufer A, Levy P, et al. Innovative pharmaceutical pricing agreements in five European markets: a survey of stakeholder attitudes and experience. Health Policy. 2018;122(5):528–532.
- Garattini L, Curto A, van de Vooren K. Italian risk-sharing agreements on drugs: are they worthwhile? Eur J Health Econ. 2015;16(1):1–3.
- Garattini L, Curto A. Performance-based agreements in Italy: ‘trendy outcomes’ or mere illusions? Pharmacoeconomics. 2016;34(10):967–969.